EyePoint Pharmaceuticals, Inc.
EYPT
$11.84
-$0.20-1.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 51.90M | 56.04M | 43.27M | 45.71M | 50.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 51.90M | 56.04M | 43.27M | 45.71M | 50.39M |
| Cost of Revenue | 185.60M | 161.66M | 133.85M | 109.28M | 98.24M |
| Gross Profit | -133.71M | -105.61M | -90.58M | -63.57M | -47.85M |
| SG&A Expenses | 55.35M | 55.76M | 55.28M | 53.40M | 50.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 240.95M | 217.41M | 189.13M | 162.68M | 149.01M |
| Operating Income | -189.05M | -161.37M | -145.85M | -116.97M | -98.62M |
| Income Before Tax | -175.20M | -146.69M | -130.78M | -103.49M | -86.74M |
| Income Tax Expenses | 183.00K | 90.00K | 90.00K | 83.00K | 83.00K |
| Earnings from Continuing Operations | -175.38 | -146.78 | -130.87 | -103.57 | -86.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -175.38M | -146.78M | -130.87M | -103.57M | -86.82M |
| EBIT | -189.05M | -161.37M | -145.85M | -116.97M | -98.62M |
| EBITDA | -187.14M | -159.64M | -144.31M | -115.78M | -97.73M |
| EPS Basic | -2.68 | -2.41 | -2.31 | -2.01 | -1.80 |
| Normalized Basic EPS | -1.67 | -1.50 | -1.44 | -1.25 | -1.12 |
| EPS Diluted | -2.68 | -2.41 | -2.31 | -2.01 | -1.80 |
| Normalized Diluted EPS | -1.67 | -1.50 | -1.44 | -1.25 | -1.12 |
| Average Basic Shares Outstanding | 258.70M | 241.98M | 225.12M | 202.74M | 186.63M |
| Average Diluted Shares Outstanding | 258.70M | 241.98M | 225.12M | 202.74M | 186.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |